Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Novartis Pharmaceuticals
Related studies linked through entity extraction aliases.
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
- Status
- TERMINATED
- Phase
- PHASE3